Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results

Revenue fell 7.9% and losses widened despite higher gross margin and strong cash reserves.

What the company is saying

Inspire Medical Systems reports a 7.9% year-over-year revenue decline to $206.7 million for Q3 2026, attributing the drop primarily to U.S. coding and reimbursement challenges. The company highlights a 20 basis point increase in gross margin to 86.0%, driven by a higher sales mix of the Inspire V system. Operating expenses rose by $23.5 million, or 12.8%, to $206.6 million, mainly due to $24.1 million in restructuring charges and a $7.0 million legal settlement, with higher legal fees partially offset by reduced marketing and stock-based compensation costs. CEO Tim Herbert frames the narrative around overcoming headwinds, focusing on education initiatives, and executing strategic priorities, while emphasizing the approval of a new CPT code for Inspire V, effective January 2028, as a future growth catalyst. The company narrows full-year 2026 revenue guidance to $850–$860 million and expects adjusted operating margin of 4.5–5.5%, diluted EPS of $(0.36) to $(0.10), and adjusted diluted EPS of $1.20 to $1.40. The tone is measured, acknowledging current challenges while projecting confidence in long-term positioning through Project Horizon and upcoming reimbursement clarity.

What the data suggests

The financials show a deteriorating trend: revenue dropped 7.9% to $206.7 million, mainly due to U.S. market pressures from coding and reimbursement issues. Gross margin improved to 86.0%, reflecting a favorable product mix shift toward Inspire V, but this was not enough to offset rising costs. Operating expenses jumped 12.8% to $206.6 million, driven by $24.1 million in restructuring charges and a $7.0 million legal settlement, resulting in an operating loss of $28.7 million and a negative operating margin of (13.9)%. Adjusted operating income was just $1.9 million (0.9% margin). The effective tax rate dropped sharply to 2.5% due to pre-tax losses and restructuring-related tax charges. Net loss for the quarter was $24.4 million, with adjusted net earnings of $4.1 million. Diluted EPS was $(0.84), adjusted diluted EPS $0.14. Cash from operations fell to $46.4 million from $68.5 million a year earlier, but total cash and investments rose by $48.5 million to $453.1 million. Full-year guidance is narrowed but still implies ongoing pressure, with high effective tax rates (120–175%) and capital expenditures of $35–$40 million. The approval of a new CPT code is a long-term positive but will not impact reimbursement until January 2028.

Analysis

The announcement is factual and restrained in tone, with no evidence of narrative inflation or exaggerated claims. The company discloses a 7.9% revenue decline, increased operating expenses, and a net loss for the quarter, all supported by detailed numerical data. Forward-looking statements are limited to narrowed full-year guidance and the anticipated impact of a new CPT code effective in 2028, which is long-term and not presented as an imminent benefit. The CEO's commentary about being 'positioned well for growth' is generic and not paired with unsupported projections or aggressive language. Capital expenditures are moderate and clearly disclosed, with no suggestion of a large, speculative outlay. The gap between narrative and evidence is minimal; the data supports a deteriorating financial trend, and the company does not attempt to obscure this with promotional language.

Risk flags

• ●Ongoing coding and reimbursement challenges in the U.S. market continue to drive revenue declines, as evidenced by a 7.9% drop in Q3 2026. Without near-term resolution, these pressures could persist or worsen, limiting growth.
• ●Operating expenses surged 12.8% due to $24.1 million in restructuring charges and a $7.0 million legal settlement, highlighting exposure to legal and restructuring risks that may not be one-off in nature.
• ●Despite strong cash reserves ($453.1 million), cash flow from operations declined to $46.4 million from $68.5 million a year earlier, signaling potential strain on future liquidity if losses persist.
• ●The new CPT code for Inspire V, while a potential growth driver, will not take effect until January 2028. This creates a multi-year execution gap during which reimbursement uncertainty may continue to weigh on results.
• ●Full-year guidance assumes a very high effective tax rate (120–175%) and ongoing capital expenditures of $35–$40 million, which could pressure net earnings and cash flow if revenue does not stabilize.

Bottom line

Inspire Medical Systems is facing significant near-term headwinds, with Q3 2026 revenue down 7.9% and a net loss of $24.4 million, mainly due to persistent U.S. reimbursement and coding issues. Gross margin improvement and a strong cash position provide some cushion, but rising operating expenses and declining cash flow from operations raise concerns about sustained profitability. The company's narrowed 2026 guidance reflects ongoing uncertainty, and while the approval of a new CPT code for Inspire V could improve reimbursement and access, its benefits will not be realized until 2028. Investors should focus on whether the company can stabilize U.S. revenue and control costs in the coming quarters. The most important takeaway is that, despite management's confidence in long-term prospects, the path to recovery is uncertain and will require successful navigation of reimbursement and expense challenges before any benefit from future coding changes is felt.

Announcement summary

(NYSE:INSP) Inspire Medical Systems, Inc. reported financial results for the quarter ended September 30, 2026. Revenue for the third quarter of 2026 decreased 7.9% to $206.7 million, primarily due to a decline in U.S. revenue driven by coding and reimbursement challenges. Gross margin increased by 20 basis points to 86.0%, attributed mainly to a higher sales mix of the Inspire V system, which carries a higher gross margin than the Inspire IV system. Operating expenses rose by $23.5 million, or 12.8%, to $206.6 million, mainly due to $24.1 million in restructuring charges, a legal settlement expense of $7.0 million, and higher legal fees, partially offset by lower marketing and stock-based compensation expenses. Operating loss for the quarter was $28.7 million, with an operating margin of (13.9)%. Adjusted operating income was $1.9 million, and adjusted operating margin was 0.9%. The effective tax rate was 2.5%, down from 26.7%, primarily due to the current period pre-tax loss and discrete tax charges related to restructuring. Net loss for the quarter was $24.4 million, while adjusted net earnings were $4.1 million. Diluted earnings per share (EPS) was $(0.84), and adjusted diluted EPS was $0.14. Net cash provided by operating activities for the quarter was $46.4 million, compared to $68.5 million in the prior year period, with the decrease mainly due to lower net earnings and lower collections on receivables. As of September 30, 2026, cash, cash equivalents, and investments increased by $48.5 million to $453.1 million compared to December 31, 2025. The company narrowed its full-year 2026 revenue guidance to a range of $850 million to $860 million, compared to the previous range of $835 million to $875 million. Adjusted operating margin for the full year is now expected to be between 4.5% and 5.5%. Diluted EPS is projected to be in the range of $(0.36) to $(0.10), and adjusted diluted EPS is expected to be between $1.20 and $1.40. The outlook assumes an effective tax rate of approximately 120% to 175% and an adjusted effective tax rate of 33% to 34%, with estimated weighted average diluted shares outstanding of approximately 28.9 million and capital expenditures between $35 million and $40 million. The AMA Editorial Panel approved a new Category I CPT code for single lead hypoglossal nerve stimulation devices, including Inspire V, set to take effect January 1, 2028. Tim Herbert, Chairman and CEO, stated that the company is focused on education initiatives and executing strategic priorities, and highlighted the approval of the new CPT code and investment in revenue growth initiatives through Project Horizon as positioning the company well for future growth. The company will host a conference call on November 2, 2026, at 5:00 p.m. Eastern Time to discuss these results.

Disagree with this article?